Form 4: Larimar Therapeutics Director Acquires Stock Options

Director Thomas Edward Hamilton acquired 19,000 stock options in Larimar Therapeutics on May 13, 2025.

Summary

• Thomas Edward Hamilton, a director of Larimar Therapeutics, acquired 19,000 stock options on May 13, 2025.
• The exercise price of these options is $1.875.
• The options vest on the earlier of May 13, 2026, or the date of the company's next annual meeting of stockholders, contingent upon continued service on the Board of Directors.
• The options expire on May 13, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition by a director, which doesn't inherently indicate positive or negative sentiment.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates a director's increased stake in the company, which can be viewed positively by investors.

Stakeholder Impact

• The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with those of the shareholders.

Key Dates

Keywords

stock options, director, Larimar Therapeutics, LRMR, Form 4, beneficial ownership, Hamilton, equity securities